Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Dec;40(12):2015-2021.
doi: 10.1007/s00296-020-04699-x. Epub 2020 Sep 18.

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Jesús Loarce-Martos  1 , Antía García-Fernández  2 , Fernando López-Gutiérrez  2 , Verónica García-García  2 , Laura Calvo-Sanz  2 , Iván Del Bosque-Granero  2 , M Andreína Terán-Tinedo  2 , Alina Boteanu  2 , Javier Bachiller-Corral  2 , Mónica Vázquez-Díaz  2
Affiliations
Observational Study

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Jesús Loarce-Martos et al. Rheumatol Int. 2020 Dec.

Abstract

The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (01/02/2020-26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. In total, 76 patients were screened. Of these, 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. With regard to these 13 patients, the median age at coronavirus disease (COVID-19) diagnosis was 68 years (range 28-76 years) and 8 (61.5%) were female. Five patients had rheumatoid arthritis, three had systemic vasculitis, two had Sjögren syndrome, and two had systemic lupus erythematosus. Additionally, seven patients (53.8%) had pulmonary involvement secondary to RMD. Eight patients (61.5%) developed severe disease leading to hospitalization, and seven developed bilateral pneumonia and respiratory insufficiency. Of the eight hospitalized patients, five (62.5%) fulfilled the acute respiratory distress syndrome criteria and three developed a critical disease and died. Our cohort had a high rate of severe disease requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is required to confirm this association.

Keywords: COVID-19; Rheumatic diseases; Rituximab; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Dr. Loarce-Martos reports personal fees from Celgene S.L.U., outside the submitted work; Dr. García-Fernández has nothing to disclose; Dr. López-Gutiérrez has nothing to disclose; Dr. García-García has nothing to disclose; Dr. Calvo-Sanz has nothing to disclose; Dr. del Bosque-Granero has nothing to disclose; Dr. Terán-Tinedo has nothing to disclose; Dr. Boteanu has nothing to disclose; Dr. Bachiller-Corral has nothing to disclose; Dr. Vázquez-Díaz reports personal fees and non-financial support from Sandoz, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Merck Sharp and Dohme, outside the submitted work.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed 24 Aug 2020
    1. Datos COVID-19 Comunidad de Madrid. https://www.comunidad.madrid/uploads/mapas_covid-19/index.html. Accessed 24 Aug 2020
    1. Hsu CY, Ko CH, Wang JL, et al. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019 doi: 10.1186/s13075-019-1997-5. - DOI - PMC - PubMed
    1. Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. 2020 doi: 10.1056/nejmc2009567. - DOI - PMC - PubMed
    1. Michelena X, Borrell H, López-Corbeto M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with _targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020 doi: 10.1016/j.semarthrit.2020.05.001. - DOI - PMC - PubMed

Publication types

MeSH terms

  NODES
admin 2
Association 1
twitter 2